Display options
Cite
Gravemann U, Kusch M, Koenig H, et al. Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System. Transfus Med Hemother. 2009;36(2):122-127doi: 10.1159/000202413.
Gravemann, U., Kusch, M., Koenig, H., Mohr, H., & Mueller, T. H. (2009). Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 36(2), 122-127. https://doi.org/10.1159/000202413
Gravemann, Ute, et al. "Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System." Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie vol. 36,2 (2009): 122-127. doi: https://doi.org/10.1159/000202413
Gravemann U, Kusch M, Koenig H, Mohr H, Mueller TH. Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System. Transfus Med Hemother. 2009;36(2):122-127. doi: 10.1159/000202413. Epub 2009 Mar 04. PMID: 20823993; PMCID: PMC2928825.
Copy Download .nbib Format: NLM
Share it on

Transfus Med Hemother. 2009;36(2):122-127. doi: 10.1159/000202413. Epub 2009 Mar 04.

Thrombin Generation Capacity of Methylene Blue-Treated Plasma Prepared by the Theraflex MB Plasma System.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

Ute Gravemann, Manuela Kusch, Herbert Koenig, Harald Mohr, Thomas H Mueller

Affiliations

  1. DRK-Blutspendedienst NSTOB, Institut Springe, Langen, Germany.

PMID: 20823993 PMCID: PMC2928825 DOI: 10.1159/000202413

Abstract

BACKGROUND: Methylene blue (MB) / light treatment is a well-known procedure for the inactivation of pathogens in fresh frozen plasma (FFP). Aim of the current study was to investigate the thrombin generation (TG) characteristics and quality of MB plasma prepared by the Theraflex MB Plasma System. METHODS: Single donor plasma units (n = 18) were MB/light-treated, with sampling before and after processing. Preparation included leukocyte depletion, addition of MB pill prior to illumination, and depletion of MB and photoproducts by filtration. Different plasma parameters and TG were measured. TG additionally was determined in solvent/detergent plasma (n = 8). RESULTS: MB/light treatment significantly affected factors V, VIII and XI, which were decreased by 9-18%. While the antigen level was not affected, fibrinogen according to Clauss was decreased by 7%, correlating with a 12% prolongation of TT and RT. The total amount of free thrombin generated, given as 'area under the curve' (AUC), was comparable for untreated (93 +/- 18% of normal plasma) and MB/light-treated plasma (95 +/- 20%). Also peak thrombin concentration was not significantly affected by treatment (94 +/- 11% (untreated) vs. 96 +/- 12% (treated)). The 'time to peak' value (TTP) was 105% of normal plasma for untreated FFP and 89% for MB-treated plasma. CONCLUSION: For plasma treated with the Theraflex MB Plasma System no profound influence of MB/ light treatment on the characteristics of thrombin generation was detected. In concordance with data from the literature, coagulation factors V, VIII and XI were decreased due to MB/ light treatment. Decrease was less than 20%.

References

  1. Transfus Apher Sci. 2006 Dec;35(3):223-33 - PubMed
  2. Biochim Biophys Acta. 1978 Jan 25;532(1):161-70 - PubMed
  3. Cell Mol Life Sci. 1997 Jan;53(1):29-33 - PubMed
  4. Transfusion. 1994 Aug;34(8):685-9 - PubMed
  5. Vox Sang. 2008 May;94(4):306-14 - PubMed
  6. Immunol Invest. 1995 Jan-Feb;24(1-2):73-85 - PubMed
  7. Thromb Haemost. 2006 Nov;96(5):553-61 - PubMed
  8. Blood Rev. 2007 May;21(3):131-42 - PubMed
  9. Transfus Apher Sci. 2007 Dec;37(3):223-31 - PubMed
  10. J Thromb Haemost. 2007 May;5(5):1084-5; author reply 1085-7 - PubMed
  11. Vox Sang. 2007 May;92(4):319-26 - PubMed
  12. Transfus Med. 2001 Feb;11(1):31-6 - PubMed
  13. Transfusion. 2003 Sep;43(9):1322-9 - PubMed
  14. Br J Haematol. 1971 Jul;21(1):43-52 - PubMed
  15. Transfusion. 2003 Sep;43(9):1238-47 - PubMed
  16. Transfus Med. 2004 Feb;14(1):39-44 - PubMed
  17. Vox Sang. 2006 Nov;91(4):285-91 - PubMed
  18. Thromb Res. 1988 Jan 15;49(2):241-51 - PubMed
  19. Vox Sang. 1992;63(3):178-85 - PubMed
  20. Transfus Apher Sci. 2005 Aug;33(1):63-9 - PubMed
  21. Transfus Med. 2006 Aug;16(4):266-75 - PubMed
  22. Transfusion. 2004 Jun;44(6):886-90 - PubMed
  23. Transfusion. 2003 May;43(5):568-75 - PubMed
  24. Br J Haematol. 2007 Oct;139(2):303-9 - PubMed
  25. Thromb Res. 1990 Oct 1;60(1):19-32 - PubMed
  26. Eur J Biochem. 1988 Feb 15;172(1):17-25 - PubMed
  27. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):249-53 - PubMed
  28. Br J Haematol. 2002 Apr;117(1):253-4 - PubMed
  29. Transfusion. 2008 Jan;48(1):108-17 - PubMed
  30. Blood Coagul Fibrinolysis. 2004 Jul;15(5):405-11 - PubMed

Publication Types